Tyra Bioscience (TYRA) AI Stock Analysis

• Market Cap: $2.06B
• Dividend Yield: N/A
• Average Volume (3M): 370.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.50
• Revenue Growth: N/A
• EPS Growth: -17.01%
• Country: US
• Employees: 60
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.57
• Shares Outstanding: 53,867,115
• 10 Day Avg. Volume: 580,167
• 30 Day Avg. Volume: 370,944
• PEG Ratio: -0.39
• Price to Book (P/B): 6.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -16.45
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -7.28K
• Enterprise Value/Ebitda: -16.57
• 1Y Price Target: $48.71
• Price Target Upside: 28.02% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): -2.36
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $40.00 ▲(5.12% Upside)
• Action: Reiterated Date: 03/05/26
• Date: Action: Reiterated 03/05/26

The score is primarily held back by weak financial performance (no revenue, widening losses, and rising cash burn), partially offset by a strong technical uptrend and improved funding flexibility from the $126M equity raise. Valuation remains challenged due to negative earnings and no dividend support.

Positive Factors

Access to capital

The $126M block sale demonstrates durable access to institutional equity capital, materially extending runway for clinical programs without adding meaningful debt. Continued ability to raise equity reduces near-term liquidity risk and supports execution of multi-stage development plans over the next 2-6 months.

Low leverage profile

A very low debt-to-equity ratio provides financial flexibility and limits fixed financial obligations, allowing the company to prioritize R&D spending and strategic options. This conservative capital structure reduces bankruptcy and refinancing risk while clinical milestones are pursued.

Focused FGFR drug discovery platform

A platform centered on FGFR biology and structure-guided design is a durable competitive asset: it can accelerate candidate generation, target resistance mechanisms, and create differentiated drugs. Platform-driven pipelines can improve R&D efficiency and partnership appeal over time.

Negative Factors

Pre-revenue with widening losses

Being pre-revenue with materially widening losses means continued reliance on external financing until commercialization or partnering. Persistent negative earnings consume equity and constrain reinvestment, increasing the long-term dilution and financing risk if clinical progress stalls.

High and worsening cash burn

Rising negative operating and free cash flow indicates accelerating cash consumption from development activities. This structural burn increases probability of future dilutive financings or partnership necessity, reducing strategic optionality and pressuring management to secure non-dilutive funding or faster clinical readouts.

Declining equity and negative ROE

The decline in shareholders' equity and substantially negative ROE show the capital base is being consumed to fund operations. This weakens the balance-sheet cushion for late-stage costs, making the firm more dependent on capital markets and potentially impairing bargaining power in collaborations.

Tyra Bioscience Business Overview & Revenue Model

Company Description

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

How the Company Makes Money

Tyra Biosciences does not sell approved products and, as a clinical-stage biotechnology company, has historically generated limited recurring commercial revenue. Its funding and cash inflows have primarily been supported by capital-raising activities (e.g., equity financings such as public offerings) rather than product sales. Potential future revenue sources are expected to include (a) sales of any drug candidates that achieve regulatory approval and are commercialized, and/or (b) payments from strategic collaborations or licensing arrangements (such as upfront payments, development and regulatory milestone payments, sales-based milestones, and royalties) if the company partners its programs; specific partnership terms and material recurring partnership revenue are null if not publicly detailed in the requested context.

Tyra Bioscience Financial Statement Overview

Summary

R&D-stage profile with $0 revenue across the provided periods, widening losses (net loss to about -$120.0M in 2025) and deteriorating cash burn (2025 operating cash flow about -$95.1M; free cash flow about -$95.3M). The balance sheet is supportive due to very low leverage (debt-to-equity ~0.02), but equity declined from 2024 to 2025, reflecting ongoing funding needs.

Income Statement

The company is still pre-revenue (revenue has been $0 across the provided annual periods), so profitability metrics are not yet established. Losses have widened materially over time, with net loss increasing from about -$9.3M (2020) to about -$120.0M (2025), and EBIT also trending more negative (about -$132.8M in 2025 vs. -$104.2M in 2024). The main strength is that results are consistent with an R&D-stage biotech model, but the clear weakness is accelerating operating losses without offsetting revenue traction in the financials provided.

Balance Sheet

Leverage is very low, with total debt of about $5.8M against stockholders’ equity of about $259.2M in 2025 (debt-to-equity ~0.02), which provides financial flexibility. However, equity has declined from about $343.2M (2024) to $259.2M (2025), reflecting ongoing losses and cash usage. Return on equity is meaningfully negative in recent years (about -46% in 2025), highlighting that the capital base is being consumed to fund operations despite the conservative debt profile.

Cash Flow

Cash generation is weak, with operating cash flow and free cash flow consistently negative and worsening in 2025 (operating cash flow about -$95.1M; free cash flow about -$95.3M) versus 2024 (about -$69.8M and -$70.4M, respectively). A relative positive is that free cash flow roughly tracks net loss (free cash flow to net income near ~1.0 in recent years), suggesting losses are not heavily driven by non-cash add-backs; however, the underlying issue remains a rising cash burn profile that increases financing dependence until revenue arrives.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-546.00K	0.00	0.00	0.00	0.00
EBITDA	-119.40M	-103.66M	-79.59M	-58.63M	-26.15M
Net Income	-119.95M	-86.48M	-69.13M	-55.33M	-26.29M
Balance Sheet
Total Assets	282.61M	363.56M	225.86M	266.18M	306.70M
Cash, Cash Equivalents and Short-Term Investments	256.00M	341.44M	203.47M	251.21M	302.18M
Total Debt	5.81M	6.22M	6.50M	2.62M	1.18M
Total Liabilities	23.43M	20.41M	21.59M	8.35M	4.96M
Stockholders Equity	259.18M	343.15M	204.26M	257.83M	301.74M
Cash Flow
Free Cash Flow	-95.28M	-70.44M	-50.91M	-50.84M	-24.41M
Operating Cash Flow	-95.14M	-69.77M	-50.14M	-50.28M	-23.75M
Investing Cash Flow	72.46M	-98.40M	-144.60M	-559.00K	-645.00K
Financing Cash Flow	8.10M	202.14M	1.54M	632.00K	311.35M

Tyra Bioscience Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 38.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TYRA, the sentiment is Positive. The current price of 38.05 is above the 20-day moving average (MA) of 34.93, above the 50-day MA of 32.03, and above the 200-day MA of 18.87, indicating a bullish trend. The MACD of 1.86 indicates Negative momentum. The RSI at 69.41 is Neutral, neither overbought nor oversold. The STOCH value of 94.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TYRA.

Tyra Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TYRA	58 Neutral	$2.06B	-13.06	-34.75%	―	―	-17.01%
KALV	57 Neutral	$830.48M	-3.32	-282.01%	―	―	-13.14%
TERN	52 Neutral	$5.22B	-6.99	-29.95%	―	―	12.45%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PVLA	49 Neutral	$1.56B	-15.28	-64.41%	―	―	―
NRIX	47 Neutral	$1.53B	-5.54	-57.51%	―	48.32%	-1.91%
GOSS	40 Underperform	$106.08M	-3.72	242.63%	―	-58.17%	-116.24%

Tyra Bioscience Corporate Events

Tyra Bioscience Raises $126 Million in Block Share Sale

On March 4, 2026, Tyra Biosciences, Inc. agreed to issue and sell 4,000,000 shares of its common stock to a large investment management firm at $31.50 per share, in a block transaction under its existing at-the-market equity offering program. The transaction is expected to generate $126 million in gross proceeds before fees and expenses, underscoring the company’s ability to tap institutional capital and potentially strengthening its balance sheet for future operational and strategic priorities.

The shares are being issued pursuant to a previously filed shelf registration statement and accompanying sales agreement prospectus that govern the at-the-market program. By executing a sizable single-investor block sale within this framework, Tyra demonstrates continued access to public equity markets, which may influence investor perception of its funding runway and financial flexibility.

The most recent analyst rating on (TYRA) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Tyra Bioscience stock, see the TYRA Stock Forecast page.